Docket: T-1472-13
Citation:
2015 FC 458
Montreal, Québec, April 14, 2015
PRESENT: The Honourable Mr. Justice Locke
|
BETWEEN:
|
|
SHIRE CANADA
INC.
|
|
Applicant
|
|
and
|
|
COBALT
PHARMACEUTICALS COMPANY AND THE MINISTER OF HEALTH
|
|
Respondents
|
|
and
|
|
SHIRE LLC
|
|
Patentee/Respondent
|
ORDER AND REASONS
I.
Background
[1]
This is a motion by the applicant, Shire Canada
Inc. (Shire), to appeal an Order of Prothonotary Tabib dated October 9, 2014
(Prothonotary Tabib’s Order) which dismissed Shire’s motion to strike certain
affidavit evidence submitted by the respondent Cobalt Pharmaceuticals Company
(Cobalt) in the present application pursuant to the Patent Medicines (Notice
of Compliance) Regulations, SOR/93-133 (the PM(NOC) Regulations).
Specifically, Shire sought to strike the affidavit of Michael Stewart and
certain portions of the affidavit of Peter Rue. In the alternative, Shire
sought to file further evidence in the form of a reply affidavit of James
Polli.
II.
Standard of Review
[2]
The standard of review of a discretionary
decision of a prothonotary is as argued by Cobalt and as acknowledged by Shire
at paragraphs 30 and 31 of its written representations in support of the
present motion: such decisions should not be disturbed unless (a) the questions
raised in the motion are vital to the final issue of the case, or (b) the order
is clearly wrong, in the sense that the exercise of discretion by the
prothonotary was based upon a wrong principle or upon a misapprehension of the
facts: Merck & Co. Inc. v Apotex Inc., 2003 FCA 488 at para 19.
There is no argument that the questions raised in the present motion are vital
to the final issue of the case. Therefore, this motion is to be decided on the
basis of whether Prothonotary Tabib’s Order was clearly wrong.
[3]
At the hearing of the present motion, Shire
strayed from its written representations and argued that a less deferential
standard of review should apply because, in addition to hearing this motion, I
will be the judge hearing the present application on its merits. Shire cited no
authority for such an exception to the well-settled test for appeal of a
prothonotary’s decision. I do not accept Shire’s argument on this point because
there are many reasons for showing deference to prothonotaries’ decisions, some
of which are unrelated to whether the judge on the appeal is also the judge on
the merits.
III.
Applicable Law
[4]
There appears to be agreement between the
parties that the question of whether the evidence at issue should be struck is
to be determined in accordance with the decision of the Federal Court of Appeal
in AB Hassle v Canada (Minister of National Health and Welfare) (2000),
7 CPR (4th) 272 (AB Hassle). In that decision, the Court observed that
the nature of proceedings under the PM(NOC) Regulations requires that
the Notice of Allegation (NOA) communicated by the “second
person” prior to the commencement of the proceeding raise all factual
and legal arguments upon which it relies to support its allegations. As stated
by Justice Hughes in Bayer Inc. v Cobalt Pharmaceuticals Company, 2013
FC 1061 at para 34, the second person “cannot craft new
arguments, or raise new allegations or new facts or new prior art documents not
set out in the Notice of Allegation.” However, the parties appear to be
agreed that this prohibition does not prevent a second person from responding
to evidence adduced and issues raised by the first person.
[5]
Therefore, the present motion is to be decided,
at least in part, on the basis of whether Cobalt’s evidence in dispute raises
new allegations or new facts, or if it is merely responsive to Shire’s
evidence.
IV.
Prothonotary Tabib’s Order
[6]
Prothonotary Tabib concluded that the Stewart
Affidavit could be responsive to Cobalt’s affidavit of Beth Burnside, and found
no prejudice to Shire in letting the judge on the merits consider the
admissibility of the evidence. Prothonotary Tabib rejected Shire’s argument
that the Stewart Affidavit was tendered to support a new ground of invalidity
of the patent in suit, Canadian Patent No. 2,348,090 (the 090 Patent).
[7]
With respect to the Rue Affidavit, Prothonotary
Tabib concluded similarly, finding that the portions in dispute do not concern
a new argument that the 090 Patent was improperly listed.
[8]
Accordingly, Prothonotary Tabib refused to
strike the evidence in question. She also refused to allow the filing of
Shire’s proposed reply evidence since it concerned the alleged new argument of
improper listing.
V.
Analysis
[9]
The present motion comes down to whether
Prothonotary Tabib was clearly wrong in determining that:
- the Stewart
Affidavit could be responsive to the Burnside Affidavit and did not
otherwise raise new factual or legal arguments;
- the portions of
the Rue Affidavit at issue do not raise new factual or legal arguments;
and
- the proposed reply evidence concerns only an issue that is not
in dispute.
A.
Stewart Affidavit
[10]
Mr. Stewart is a patent agent registered in
Canada and the U.S. His affidavit puts in evidence the file history of the 090
Patent, as well as a number of U.S. patents that are related to the 090 Patent
together with their file histories. The Stewart Affidavit also comments on
these file histories.
[11]
Shire argues that Prothonotary Tabib was clearly
wrong in determining that the Stewart Affidavit could be responsive to the
Burnside Affidavit. Shire notes correctly that the Stewart Affidavit makes no
mention of the Burnside Affidavit and that Mr. Stewart was not even shown the
Burnside Affidavit. Shire also notes correctly that Cobalt’s NOA makes no
mention of the documents attached to the Stewart Affidavit.
[12]
Cobalt argues that the Stewart Affidavit is
admissible on a number of grounds. One of these is that the Burnside Affidavit
refers to corrections made to the 090 Patent and to “corresponding”
U.S. patents and various corrections made to them, but does not provide the underlying
documents. Cobalt argues that it is appropriate to put the documents and facts
properly in evidence, and that these documents and facts are relevant for a
number of reasons. Much of the information Cobalt seeks to keep in evidence
concerns figure 7 of the 090 Patent which, by virtue of the position Shire has
taken in the present proceeding, has become central to the asserted invention
of the 090 Patent. Cobalt wishes to establish that figure 7 was introduced
after the claimed priority date, which may affect the claim date of certain
claims, and hence the citability of certain asserted prior art. Cobalt also
wishes to show that it was not necessary to draft claims in relation to figure
7, which could support its allegation that the 090 Patent violates subsection
86(1) of the Patent Rules, SOR/96-423. Moreover, figure 7 is relevant to
Cobalt’s argument of avoidable ambiguity. Still further, Cobalt wishes to
establish that the y-axis in figure 7 measures a single enantiomer of
amphetamine, rather than the total amount of amphetamine, which may be relevant
to the issue of infringement. Without deciding whether these various arguments
have merit, I am not prepared to find that Prothonotary Tabib was clearly wrong
in finding that the Stewart Affidavit could be responsive to the Burnside
Affidavit. I am also not inclined to make a different decision at this stage as
the judge who will hear the application on the merits.
[13]
Shire argues that it is well-accepted in Canada
that claims are to be construed without reference to extrinsic evidence, such
as the prosecution history of the 090 Patent or of related foreign patents, and
therefore the file histories in question are not relevant. Cobalt counters that
recent authorities cast doubt on whether the prohibition against extrinsic
evidence is as broad as Shire asserts. Cobalt argues that it should be allowed
to explore this argument and to adduce the necessary supporting evidence on the
issue. Again, without deciding whether Cobalt’s position on this point has
merit, I am of the view that it should be allowed to make the argument.
[14]
Shire points out that Mr. Stewart, as a patent
agent, has no expertise concerning how the claims in issue should be construed,
and argues that his evidence should be struck on this basis. While I
acknowledge the limited scope of Mr. Stewart’s expertise, it is my view that
this goes more to the weight to be given to his testimony rather than its
admissibility.
[15]
Finally, Shire cites the rule in Browne v
Dunn (1893), 6 R 67 (HL) to argue that the Stewart Affidavit is
inadmissible to counter the Burnside Affidavit since it was not put to Dr.
Burnside during her cross-examination. I am not satisfied that this rule
applies to the present situation. After having heard Shire on this point, it is
not clear to me what aspects of the Stewart Affidavit should have been put to
Dr. Burnside and what sorts of clarifications she might have been able to offer
if those aspects of the Stewart Affidavit had been put to her.
B.
Rue Affidavit
[16]
Shire argues that the portions in dispute of the
Rue Affidavit assert that its patented product, Adderall XR, does not fall
within the scope of claim 22 of the 090 Patent. Since this assertion was not
made previously, Shire argues that it goes to a new argument, possibly but not
necessarily an improper listing argument. Shire argues that the portions in
dispute should therefore be struck.
[17]
Having read the portions in dispute, I am
satisfied that they do not assert that Adderall XR actually falls outside the
scope of claim 22. Rather, they are part of an argument that the claim
construction in the affidavit of James Polli should not be followed because it
leads to the conclusion that Adderall XR is outside the scope of claim 22.
[18]
In light of this, as well as the explicit
indication by Cobalt that improper listing is not in issue, I am not prepared
to find that Prothonotary Tabib was clearly wrong in refusing to strike the
portions in dispute of the Rue Affidavit.
C.
Reply Evidence
[19]
In view of my finding concerning the Rue
Affidavit, it follows that Prothonotary Tabib was not clearly wrong when she
found that the proposed reply evidence was not necessary or relevant. She did
not err in failing to conduct an assessment using the four-point test set out
in Merck-Frosst v Canada (Health), 2009 FC 914 at para 10.
VI.
Conclusion
[20]
For the reasons set out above, I have concluded
that Prothonotary Tabib made no error in her Order, and that the present motion
should be dismissed with costs. Because time did not permit during the hearing
of the present motion, I agreed to allow the parties to make written
representations as to costs after release of the present decision.